Long-term renal outcomes of patients with COVID-19: a meta-analysis of observational studies

Zhang, Yuhui; Zhao, Youlu; Wang, Jinwei; Zheng, Xizi; Xu, Damin; Lv, Jicheng; Yang, Li

doi:10.1007/s40620-023-01731-8

Cited by 7 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Individuals who survived acute COVID-19 may be at higher risks of developing new clinical disorders and/or accelerated disease progression of existing disorders. Higher incidences of diabetes [68][69][70], hypertension [71], kidney disorders [72,73] among others have been reported in individuals post COVID-19 compared to non-COVID matched controls. Worsening of disease progression of existing clinical disorders have been reported in patients with hypertension [74,75], kidney disease [76], multiple sclerosis [77][78][79][80][81][82], dementia [83][84][85] and other neurological conditions [84][85][86][87][88][89] post COVID-19 compared to non-COVID matched controls.…”

Section: New Clinical Disorders and Accelerated Disease Progressionmentioning

confidence: 96%

A Comprehensive Global Review of Epidemiology, Clinical Management, Socio-Economic Impacts and National Responses of Long COVID with Future Research Directions

Song,

Cui

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Long COVID, characterized by a persistent symptom spectrum following SARS-CoV-2 infection, poses significant health, social, and economic challenges. This review aims to consolidate knowledge on its epidemiology, clinical features, and underlying mechanisms to guide global responses; Methods: We conducted a systematic literature review, analyzing peer-reviewed articles and reports to gather comprehensive data on long COVID’s epidemiology, symptomatology, and management approaches; Results: Our analysis revealed a wide array of long COVID symptoms and risk factors, with notable demographic variability. The current understanding of its pathophysiology suggests a multifactorial origin yet remains partially understood. Emerging diagnostic criteria and potential therapeutic strategies were identified, highlighting advancements in long COVID management.; Conclusion: This review highlights the multifaceted nature of long COVID, revealing a broad spectrum of symptoms, diverse risk factors, and the complex interplay of physiological mechanisms underpinning the condition. Long COVID symptoms and disorders will continue to weigh on healthcare systems in years to come. Ad-dressing long COVID requires a holistic management strategy that integrates clinical care, social support, and policy initiatives. The findings underscore the need for increased international cooperation in research and health planning to address the complex challenges of long COVID. There is a call for continued refinement of diagnostic and treatment modalities, emphasizing a multidisciplinary approach to manage the ongoing and evolving impacts of the condition.

show abstract

Section: New Clinical Disorders and Accelerated Disease Progressionmentioning

confidence: 96%

A Comprehensive Global Review of Epidemiology, Clinical Management, Socio-Economic Impacts and National Responses of Long COVID with Future Research Directions

Song,

Cui

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Beyond the immune system, LC affects most organs and organ systems in the body, including the heart [3][4][5], lungs, brain [6][7][8][9][10], kidneys [11][12][13], liver, and gut in general [14][15][16], including the spleen, pancreas [17][18][19][20][21][22], and also the reproductive system [23,24]. Resulting symptoms include chronic fatigue, shortness of breath, postural orthostatic tachycardia syndrome (POTS), palpitations, myalgias, arthralgias, cognitive impairment, headaches, sleep disturbances, secondary anxiety, depression, nausea, and diarrhea.…”

Section: Introductionmentioning

confidence: 99%

Long COVID: Long-Term Impact of SARS-CoV2

Makhluf,

Madany,

Kim

2024

Diagnostics

View full text Add to dashboard Cite

Four years post-pandemic, SARS-CoV-2 continues to affect many lives across the globe. An estimated 65 million people suffer from long COVID, a term used to encapsulate the post-acute sequelae of SARS-CoV-2 infections that affect multiple organ systems. Known symptoms include chronic fatigue syndrome, brain fog, cardiovascular issues, autoimmunity, dysautonomia, and clotting due to inflammation. Herein, we review long COVID symptoms, the proposed theories behind the pathology, diagnostics, treatments, and the clinical trials underway to explore treatments for viral persistence, autonomic and cognitive dysfunctions, sleep disturbances, fatigue, and exercise intolerance.

show abstract

“…While the impact of severe COVID-19 on kidney function has been extensively studied [1,3], the longterm effects of a moderate course of the disease on kidney outcomes have not been as thoroughly investigated. A meta-analysis of observational studies involving 6976 patients with COVID-19-associated acute kidney injury and 5223 COVID-19 patients without acute kidney injury found that patients with more comorbidities tend to have a higher renal non-recovery rate after COVID-19 [5]. For COVID-19 patients without acute kidney injury, a decrease in kidney function may occur during long-term follow-up [5].…”

mentioning

confidence: 99%

“…A meta-analysis of observational studies involving 6976 patients with COVID-19-associated acute kidney injury and 5223 COVID-19 patients without acute kidney injury found that patients with more comorbidities tend to have a higher renal non-recovery rate after COVID-19 [5]. For COVID-19 patients without acute kidney injury, a decrease in kidney function may occur during long-term follow-up [5]. This suggests that moderate COVID-19 can have a lasting impact on kidney health, which may become apparent months after the initial infection [5,6].…”

mentioning

confidence: 99%

“…For COVID-19 patients without acute kidney injury, a decrease in kidney function may occur during long-term follow-up [5]. This suggests that moderate COVID-19 can have a lasting impact on kidney health, which may become apparent months after the initial infection [5,6]. The current understanding of the burden of chronic kidney disease (CKD) that develops after COVID-19 is still limited, highlighting the need for long-term follow-up and monitoring of patients who have recovered from COVID-19, regardless of the severity of their disease.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The link between moderate COVID-19 and delayed manifestation of glomerulonephritis: Insights from cluster analysis of TGF-β1 and VEGF levels

Zub,

Horban,

Kulachek

2024

Ukr. J. Nephrol. and Dial.

View full text Add to dashboard Cite

Recent data reveal delayed pathological kidney changes occurring 8-12 months post-moderate COVID-19, often detected for the first time. While severe COVID-19 leads to interstitial and subsequent glomerular lesions, the predominant changes in moderate cases remain elusive. This study aimed to investigate the potential association between moderate COVID-19 and the manifestation of glomerulonephritis (GN). Methods. This cross-sectional study included 25 patients with stage 1-2 GN and a history of moderate COVID-19 8-12 months before the onset of GN, 27 individuals without GN who experienced COVID-19, and 20 healthy subjects without a history of COVID-19. Transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) levels in blood and urine were measured using enzyme-linked immunosorbent assay. Cluster and classification data mining methods were utilized for these markers to assess potential relationships between moderate COVID-19 and GN manifestation. Results. A significant increase in blood and urine TGF-β1 and VEGF levels was found in GN patients with a history of moderate COVID-19 (p<0.05), while elevated blood VEGF was observed in those without GN (p<0.05). Cluster analysis affirmed the correlation, emphasizing that urinary TGF-β1 within the range of 1.352 to 5.693 pg/ml and urinary VEGF < 214.12 pg/ml serve as classification rules for predicting GN. Conclusions. The cluster and classification analysis method for TGF-β1 and VEGF levels can be utilized in clinical practice to predict the development of GN in the long-term post-COVID period.

show abstract

Long-term renal outcomes of patients with COVID-19: a meta-analysis of observational studies

Cited by 7 publications

References 47 publications

A Comprehensive Global Review of Epidemiology, Clinical Management, Socio-Economic Impacts and National Responses of Long COVID with Future Research Directions

A Comprehensive Global Review of Epidemiology, Clinical Management, Socio-Economic Impacts and National Responses of Long COVID with Future Research Directions

Long COVID: Long-Term Impact of SARS-CoV2

The link between moderate COVID-19 and delayed manifestation of glomerulonephritis: Insights from cluster analysis of TGF-β1 and VEGF levels

Contact Info

Product

Resources

About